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Purpose: This study investigated mortality rate, early CD4 responses, pattern of ARVs substitutions and 
medication adherence of HIV-infected patients on first-line triple combination antiretroviral therapy (ART) 
in Central Hospital, Benin City, Nigeria. 
Methods: A retrospective assessment of 196 HIV-infected patients on first-line combination ART 
regimens was performed following 18 months of therapy. Medication adherence assessment of a 69-
patient follow-up target group was based on a study-specific questionnaire. Paired sample t-test and 
simple linear correlation were used to test the association of the CD4-cell counts at different time 
intervals. Kaplan-Meier model was used to assess survival functions while log-rank test was applied to 
assess statistical difference at 95 % confidence interval (CI). Mean age of participants was 33.6 years 
(95 % CI, 32.1 - 35.2; 67.9 % were females. 
Results: At ART initiation, 27.0 % were at WHO clinical stage II, 47.0 % at stage III. Mortality rate (N = 
196) was 20.3 deaths per 100 patient-months; 31.6 % occurred in < 30 days while 52.6 % occurred 




) at ART initiation was 179.2 which 
increased to 328.5 at
 
3 months, 325.6 at 6 months, 357.4 at 12 months, and 366.7 at 18 months, (p < 
0.01). Patients started on stavudine-based or efavirenz-based regimens were considerably more likely 
to have that drug substituted, compared to patients started on zidovudine-based or nevirapine-based 
regimens. The level of adherence reported after 18 months on ART was 73.8 %.  
Conclusion: In this setting, patients receiving ART showed significant improvements
 
in CD4-cell status 
but adherence level was relatively poor. Patients were more stable on zidovudine-based or nevirapine-
based regimens than on stavudine-based or efavirenz-based regimens. Early mortality rate was high, 
indicating a need for early interventions.   
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INTRODUCTION 
 
Epidemiological surveillance of HIV/AIDS in 
Nigeria showed an increasing prevalence 
from 0.000001% in 1986 to 0.22 % in 1987, 
1.8 % in 1991, 3 % in 1992, 3.8 % in 1993, 
4.5 % in 1996, 5.4 % in 1999, and 5.8 % in 
2001 [1]. The 2003 surveillance recorded a 
slight drop to 5.0%; this translates to 3.8 
million Nigerians living with HIV - about 20 % 
of the HIV/AIDS burden of the African 
continent and 10 % of the global HIV/AIDS 
burden. There was a further slight drop in 
2005 to 4.4 % [2,3].
 
The epidemic in Nigeria 
can be described as heterogeneous, with 
various communities in different stages. 
Young people (age 15 – 24 years) constitute 
a large proportion of those infected, while 
younger ages, primary and secondary 
education levels, were associated with higher 
risk of HIV infection with 5.9 % and 5.4 % 
prevalence, respectively [1,4]. The problem of 
HIV/AIDS in Nigeria further compounds the 
nation’s poor health indices. The Nigerian 
antiretroviral therapy (ART) guideline for 
initiating ART in adults and adolescents is 
dependent on WHO clinical staging and 
availability of CD4-cell count testing [2], and 
endorses largely the WHO guideline on ART 
initiation. 
 
In a study by Bolton-More et al, the results 
showed that patients starting a zidovudine-
based regimen or efavirenz-based regimen 
were considerably more likely over time to 
have that drug substituted, compared with 
patients starting a stavudine-based regimen 
or nevirapine-based regimen respectively [7]. 
In another study at Chiradzulu District of 
Malawi by Ferradini et al, a simplified HAART 
programme was scaled up and survival 
indicators - CD4 count evolution, virological 
response, and adherence to treatment - 
analyzed in adults who started HAART six 
months or more before the analysis. At 
follow-up (median 8.3 months), 74 % were 
still on HAART, 19 % had died, 7 % were lost 
to follow-up, and 0.5 % discontinued 
treatment. The study showed that WHO 
stage IV, male sex, and baseline CD4 count 
lower than 50 cells per mµL were 
independent determinants of death in the first 
6 months. At 12 months, the probability of 
individuals still in care was 0.76 and the 
median CD4 gain was 165 cells per mµL. Of 
several indicators measuring adherence, self-
reported poor adherence (< 80%) in the past 
4 days was the best predictor of detectable 
viral load [8]. Recent studies demonstrated 
the long-term effectiveness of antiretroviral 
therapy (ART) in a developing country urban 
setting [9,10]. These studies suggest the 
importance of monitoring ART patients more 
closely over the first year, even if six-month 
immunological and virological responses 
appear to be good. 
 
 
The effectiveness of HIV/AIDS management 
depends critically on the efficacy of the 
antiretroviral drugs (ARVs) against the virus 
and adherence to medications. Recent 
studies indicate that triple combination ART 
regimens have proved efficacious in 
industrialised countries in response to 
HIV/AIDS but the prolonged effectiveness of 
ART in a developing countries is not well 
established. Furthermore, the efficacy of 
ARVs might not be the same for some HIV 
strains present in Africa [7-9]. The high cost 
of ART intervention, complicated procedures, 
inadequate infrastructures for following up 
patients and delivering medicines regularly, 
stigma and discrimination make access to 
care and support more difficult for HIV-
infected patients. Misconceptions, cultural 
beliefs, poor socio-economic indices and 
ignorance are among the factors that could 
constitute the greatest challenge to wide 
acceptance and adherence to ART in Africa. 
Since adherence is the cornerstone of 
successful ART [11-16], there is a need to 
appraise the treatment outcomes of ART 
interventions against these factors which are  
considered as obstacles to mounting 
concerted ART programmes in Nigeria.  
 
The evaluation of the effectiveness of 
combination ART regimens in the 
management of HIV positive patients in 
Nigeria is particularly important because the 
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supporting efficacy data are scanty. This 
study aims to document the evidence of ART 
efficacy in Edo State, Nigeria. Edo, one of the 
36 States in Nigeria, has a population of over 
3.2 million and an estimated number of 
>140,000 people living with HIV. About 
70,000 people in this state are in need of HIV 
comprehensive care services [3,5,6]. The 
objectives of this retrospective investigation 
were, therefore, to describe early CD4-cell 
response and mortality rate of HIV-infected 
patients on triple combination ART after 18 
months, to assess the patients’ pattern of 
ARVs substitution within the first-line ART 
regimens, and to assess medication 
adherence of those patients active on 






A retrospective assessment of ART patients 
was performed using routinely collected 
clinical and outcome data from the patients’ 
hospital records. Medication adherence of 
patients active on treatment after 18 months 
of ART was prospectively assessed using the 




This study was carried out in Central Hospital 
Benin, a secondary public health care facility 
in Benin City, Nigeria which offers 
comprehensive HIV care services, starting 
October 2005. We obtained administrative 
approval from the management of the 





The study sample was a group of 196 
patients, who enrolled and commenced ART 
1
st
 October to 31
st
 December, 2005. A sub-
sample of the HIV-positive patients that were 
active on treatment as of October 12, 2007 
was selected for a follow-up medication 
adherence. The sample size for this 
subgroup was statistically determined from 
the population to be 64 out of 196 and hence 




All HIV positive patients who were enrolled 
and commenced ART within the study period, 
and refilled their prescriptions at the 
Pharmacy Department of the facility were 
included. Only the patients indicated above 
who were active on treatment as at October 
12, 2007 were included for medication 
adherence assessment. Participants 
consented to their inclusion. All those 
patients who did not meet the required 
criteria or give informed consent were 
excluded from the study.  
 
Data collection  
 
An unobtrusive technique was used to collect 
relevant data from the manually maintained 
records of the 196 participants using a 
structured instrument. Twenty patients were 
used in the pilot study for this aspect of the 
investigation. A study-specific questionnaire 
was administered to the sub-sample of 69 
patients. This was done over a period of 
three and half months as this sub-sample had 
varying medication refill appointment dates. 
Similarly, 5 patients were involved in the pilot 
study prior to the main data collection. A 
researcher and two trained assistants 




The data were analyzed using SPSS version 
10. Paired sample t-test and simple linear 
correlation were used to test the association 
of the CD4-cell counts at different time 
intervals. Kaplan-Meier model was used to 
assess survival functions stratified by 
baseline CD4-cell count and WHO clinical 
stage, and the log-rank test was used to 
assess statistical difference among groups 
(for equality of survival distributions). 
Mortality rates overall, at < 30 days, 30 – 
60days, 61 – 120 days and > 120 days were 
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determined using the Life Table. All reported 
P-values were 2-sided, and P < 0.05 was 




Socio-demographic characteristics of 
patients  
 
Of the 196 study participants, 194 (99.0 %) 
were treatment-naïve while 2 (1.0 %) were 
already receiving ART prior to enrollment. 
The mean age of the 196 patients at initiation 
of antiretroviral treatment was 33.6 years (95 
%CI, 32.1 - 35.2).  Other socio-demographic 
characteristics of the patients are presented 
in Table 1.   
 




available for 178 
patients (90.8 %) with a mean value of 56.6 
kg while 18 (9.2 %) had no documented 
baseline weights; the median CD4-cell count 
at initiation of antiretroviral treatment was 101 
(IQR, 35 - 206) cells/mm
3
. Those that were 
ART-eligible and initiated treatment based 
exclusively on the CD4-cell count result was 
142 (72.4 %), while a few (21.4 %) were 
based exclusively on the clinical staging. Pre-
treatment medication adherence counselling 
was given to 193 (98.5 %) patients while 3 
(1.5 %) had no documentation of this service 
(Table 2). 
 
Experience with first-line antiretroviral 
drug regimens 
 
The 196 patients were started on 
antiretroviral first-line drug regimen and 
remained on it until the last medication refill 
visit in the Pharmacy records. Of 196 patients 
initiating ART, 40.8 % were placed on 
stavudine+lamivudine+nevirapine, 46.9 % on 
zidovudine+lamivudine+ nevirapine, 7.7 % on 
zidovudine +lamivudine+efavirenz, while 4.6 
% were placed on stavudine+ lamivudine+ 
efavirenz. There were no switches from first-
line regimens to second-line or salvage 
regimens. 
 
Overall, 14.8 % patients had single-drug 
substitution of their nucleoside
 
reverse 




transcriptase inhibitor and non-nucleoside 
reverse transcriptase inhibitor (i.e., 
“stavudine+nevirapine” substituted to 
“tenofovir+efavirenz”) while 5.1 % had single-
drug substitutions of their non-nucleoside
 
reverse transcriptase inhibitors. These 
substitutions were due to few cases of drug 
intolerance,
 
toxicity, or pregnancy, and many 
cases of undocumented reasons. Of 45.4 % 
patients initiated with stavudine-based 
regimen,
 
15.7 % switched from stavudine to 
zidovudine. Additionally, 13.1 % of 54.6 % 
patients initiated with zidovudine-based 
regimen switched from zidovudine to 
stavudine. Out of 87.8 % patients receiving a 
nevirapine-based regimen, 3.5 %
 
switched to 
efavirenz (of which 33.3 % switched back to 
nevirapine), while of 12.2 % patients starting 
an efavirenz-based regimen, 3.5 %
 
switched 




As of October 12, 2007, out of the total 196 
patients, 19.4 % were documented to have 
died over 187 patient-months of follow-up 
(mortality rate of 20.3 deaths per 100 patient-
months); 38.8 % were active and still on 
treatment at the facility, 6.6 % transferred out 
to other facilities; 3.0 % stopped treatment on 
medical advice, of which 83.3 % were due to 
pregnancy and 16.7 % documented to have 
gone on drug holiday based on medical 
advice due to high CD4-cell count. A total of 
27.6 % of patients could not be followed up 
due to logistic reasons while 4.6 % patients’ 
hospital case notes were missing and could 
not be traced.  
 
Mortality in ART patients 
 
The actual causes of death in these cases 
were not documented. Of the 38 dead 
patients having a baseline mean weight of 
49.1 Kg and mean age of 36.0 years, the 
Agu  et al 
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Table 1: Socio-demographic characteristics of patients 
 
Characteristics Frequency (N=196) % 
   SEX 
Male 63 32.1 
Female 133 67.9 
AGE 
≤15  9 4.6 
16-25 25 12.8 
26-35 79 40.3 
36-45 62 31.6 
46-55 16 8.2 
≥56 5 2.5 
MARITAL STATUS 
Single  60 30.6 
Married 104 53.1 
Widow(er) 22 11.2 
Divorced/Separated 10 5.1 
EDUCATIONAL STATUS 
None 11 5.6 
Primary 69 35.2 
Secondary 70 35.7 
Post Secondary 31 15.8 
Not indicated 15 7.7 
OCCUPATIONAL STATUS 
Unemployed 72 36.7 
Employed 25 12.8 
Self-employed 49 25.0 
Not indicated 44 22.4 
Retired 1 0.5 
Student 5 2.6 
  
 
Table 2: Baseline clinical characteristics 
 
Characteristics Frequency (N=196)                       % 
WHO Clinical Stage 
I 42 21.4 
II 53 27.0 
III 92 47.0 
IV 6 3.1 




<10 21 10.7 
10–49 44 22.4 
50–100 31 15.8 
101–200 46 23.5 
201–350 25 12.8 
>350 26 13.3 
Not indicated 3 1.5 
Functional Status 
Working 147 75.0 
Ambulatory 35 17.8 
Bed-ridden 5 2.6 
Not indicated 9 4.6 
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Table 3: Mortality in ART patients  
 
baseline median CD4-cell count at initiation 
of antiretroviral treatment was 44 (IQR, 7 to 
85) cells/mm
3
. 2.6 % had no documented 
baseline CD4-cell count but presented at 
stage IV. Of the dead cases, 81.6 % 
presented for treatment at either stage II or 
III, while those that presented at WHO clinical 
stage III, 63.2 %, were more than 3-fold 
higher than those that presented at WHO 
clinical stage II (18.4 %); 7.9 % were stage I 
and 10.5 % were stage IV. In terms of 
functional status, 63.2 % were either 
ambulatory (55.3 %) or bedridden (7.9 %) at 
the time of presentation for treatment while 
36.8 % were working.  
 
The mean treatment duration before death 
was found to be 282.5 (95 %CI, 243.2 to 
321.9) days while the mortality rate was 
20.32 deaths per 100 patient-months (Table 
3).  
 
The mean survival times before death for the 
ART patients with a baseline CD4-cell Count 
of < 50 and 50–100 cells/mm
3
 were least for 
baseline stage IV, being 528.5 and 351.0 
days, respectively, but there was no 
significant difference (p > 0.05) for both CD4-
cell count categories for baseline stages I – 
IV (< 50cells/mm
3
, p = 0.3866; and 50–
100cells/mm
3
, p = 0.4578). Considering the 
baseline functional status, the mean survival 
times before death for the ART patients 
working and ambulatory were also least for 
baseline stage IV, yielding 56.0 and 434.0 
days respectively, but there was a significant 
difference (p < 0.05) for the category working 
at baseline WHO clinical stage I – IV (p = 
0.0296) while that of ambulatory patients was 
not significantly different for baseline WHO 
clinical stage I – IV (p = 0.1710).  
 
Loss to follow-up 
 
Of the 54 patients lost to follow-up, their 
baseline mean weight was 56.2 kg and mean 
age was 30.8 (IQR, 25 - 37) years. The 
median CD4-cell Count at initiation of ART 
was 142.5 (IQR, 50.5 – 296.0) cells/mm
3
. Of 
these patients, 61.1% had baseline CD4-cell 
Count > 100 cells/mm
3
 while 38.9 % had 
baseline CD4-cell Count of ≤ 100cells/mm
3
 of 
which 25.9 % were < 50 cells/mm
3
. That 
compared considerably better to the baseline 
parameters for the death cases reported 
above. Those presented for treatment at 
either stage I (33.3 %) or stage II (27.8 %) 
were 61.1 %  while 35.2 and 3.7 % were at 
stages III and IV, respectively. For functional 
status, 90.7 % was reported to be working 
while 5.6 % were ambulatory and 3.7% were 
bedridden. Of the 147 patients that had a 
working functional status, loss to follow-up 
patients contributed 33.3 %. 
 
The mean duration of treatment before loss 
to follow-up was 392.3 (95 %CI, 350.8 to 
433.7) days. Of 54 patients lost to follow-up, 
24.1 % were lost to follow-up in < 30 days of 










(deaths per 100 
patient-months) ±SD 
Overall 196 38 187 
 
20.32±0.66 
< 30 days 
 
187 12 168 7.14±0.51 
30–60 days 137 4 133 3.01±0.06 
 
61–120 days 125 2 123.5 1.62±0.01 
 
> 120 days 115 20 113.5 17.62±0.11 
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180 days and 66.7% post-180 days of 
treatment. 
 
Patients active on ART at the end of 18 
months 
 
Of the 76 patients still on treatment, the 
baseline mean weight was 59.5 kg with a 
mean age of 34.4 (IQR, 29 to 39.25) years 
and the median pre-treatment CD4-cell Count 
of 113 (IQR, 37-190) cells/mm
3
. Of these, 
52.6 % had baseline CD4-cell Count > 100 
cells/mm
3
 while 47.4 % had baseline CD4-
cell Count of ≤ 100 cells/mm
3
 of which 34.2 % 
were < 50 cells/mm
3
. All the patients received 
pre-treatment medication adherence 
counselling. The pre-treatment WHO Clinical 
staging of this category of patients comprised 
15.8 % at stage I, 34.2 % at stage II, 50.0 % 
at stage III, and none was at stage IV while 
the baseline functional status was 86.8 % 
working, 13.2 % ambulatory, and none was 
bedridden.   
 
CD4-cell Count changes over time 
 
The CD4-cell response analysis was limited 
to 186 patients
 
who had a baseline CD4 
measurement. The mean
 
CD4-cell count at 
ART initiation was 179.2 (95 %CI, 143.6 - 
220.9) cells/mm
3
 and increased to 328.5 (95 





(80.3 % increase from the mean baseline 
value) among the 75 of 135 (55.6 %) active 
patients who
 
had been enrolled long enough 
to have a 3-month measurement. This 
increased
 
to 325.6 (95 %CI, 290.5 - 360.6) 
cells/mm
3
 at 6months (78.7 % increase from 
the mean baseline value) among the 62
 
of 
118 (52.5 %) active patients enrolled long 
enough to have a 6-month
 
measurement. At 
12 months, it increased further to 357.4 (95 
%CI, 320.4 - 394.3) cells/mm
3
 (96.1 % 
increase from the mean baseline value) 
among the 55 - 98 (56.1 %) active patients 
enrolled long enough to
 
have a 12-month 
measurement, and finally to 366.7 (95 %CI, 
328.3 - 405.1) cells/mm
3
 at 18 months (101.2 
% increase from the mean baseline value) 
among the 66 of 76 (86.8 %) active patients 
enrolled
 
long enough to have an 18-month 
measurement. The percent increase from the 
patients’ baseline CD4-cell Counts 
(cells/mm
3
) at the different time intervals was 
significant at both 0.01 and 0.05 probability 
levels (p < 0.01) but there was no statistical 
difference between the following pairs of 













month (p > 0.05). The correlation of the CD4-
cell Counts measured at the different time 
intervals was found to be positive and 
statistically significant at 0.05 probability 
level.  
 
Medication adherence  
 
Of the 69 patients (90.8 %) that were 
reached, out of those 76 patients still on 
treatment, there were 65.2 % females and 
34.8 % males. The age distribution of the 69 
patients reached at the time of assessment 
showed that a majority of them (68.1 %) were 
between the ages of 26 and 45 years, 18.9 % 
patients were above 45 years while 13.0 % 
were below 25 years. A majority of the 
patients (55.1 %) were married, 26.1 % were 
single while 17.4 % and 1.4 % of the patients 
were widowed and either divorced or 
separated, respectively. Only 17.4 % had 
post-secondary education while 79.7 % had 
either secondary school (42.0 %) or primary 
school education (37.7 %). The greater 
percentage of patients (79.7 %) were 
employed, including those that were self-
employed while only a small proportion were 
unemployed (11.6 %) and 7.2 % were 
students.  
 
Of the 69 patients, 89.9 % reported knowing 
the benefits of antiretroviral therapy (of which 
almost all respondents, 98.4 % got it rightly 
stated) while 10.1 % reported not knowing 
the benefits of ART. A majority of the 
respondents, 84.1 %, had a good knowledge 
of the importance of medication adherence; a 
few, 14.5 %, did not, while 1.4 % was not 
sure of this. The respondents reported a 
good therapeutic relationship with the 
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healthcare providers with a mean score of 
88.4 %.  
 
All the 69 respondents reported receiving 
medication adherence counseling before 
starting ART. On following the scheduled 
specific timing for taking the medications, the 
respondents had a mean score of 64.1 % 
while the mean score for taking the right drug 
in the right dose at the right frequency, 
irrespective of the specific timing, was 83.5 
%. Overall, the 69 respondents recorded 73.8 
% level of adherence to medications.  
 
The patients that reported not missing any 
dose of their medications were 35 (50.7 %) 
while 34 (49.3 %) had missed one or more 
pills (of which 30, or 88.2% of them, missed 6 
doses and less) in the previous two months. 
The occupation of the respondents was 
associated with adherence (p = 0.00142) 
while educational status of the respondents 
was not (p= 0.0971). 
 
The three most reported reasons for missed 
doses were: busy working or at school (41.9 
%), patient moved away from home or 
travelled (19.8 %), and forgetfulness (14.0 
%). Of the 69 respondents, 59.4 % were 
taking one to three pills per day while 36.2 % 




Analysis of the demographic profile of the 
patients showed that a majority of those most 
at risk of HIV infection were youths and the 
proportion of females in the treatment group 
was more than two-fold greater than that of 
the males. This is consistent with a recent 
study [3]. Almost all ART initiation among the 
participants was done in line with the 
provision of the Nigeria ART guidelines [2]. 
 
A large proportion of the patients presented 
very late for treatment with very poor baseline 
parameters such as CD4-cell count and 
WHO Clinical stage; for example, half 
presented for treatment with WHO Clinical 
stage of either III or IV. This finding supports 
the need for a rapid scale-up of counselling 
and testing for early detection of 
asymptomatic cases in developing countries. 
The study finding is also consistent with the 
results of Bolton-more et al, that patients 
starting a zidovudine-based regimen or 
efavirenz-based regimen were considerably 
more likely over time to have that drug 
substituted, compared with patients starting a 
stavudine-based regimen or nevirapine-
based regimen respectively [7]. The 
participants were stable on the first-line 





-line antiretroviral regimens.  
 
The proportion of the participants still on 
treatment at the end of 18 months period was 
relatively low compared to the study findings 
of Ferradini et al [8] while the number of fatal 
cases was similar but loss to follow-up was 
higher. Mortality rate was high probably due 
to poor baseline parameters or late 
presentation for treatment. The findings 
showed that a considerably high percentage 
of patients with good CD4-cell response 
presented relatively early for treatment at a 
relatively higher baseline CD4-cell Count, 
stage I or II and better functional status, 
compared to the reported dead cases. 
Therefore, relatively high baseline 
parameters with good adherence could be 
considered as good prognostic factors.  
 
In this study, patients receiving ART showed 
significant improvements
 
in CD4-cells status 
at 3, 6, 12 and 18 months of antiretroviral 
therapy. This is consistent with recent studies 
[8-10]. Therefore, the early immunological 
response of HIV-infected patients on ART 
after a period of 18 months was considerably 
good in our setting. But mortality within the 
first 120 days of starting therapy was high. 
Although
 
many patients were ill at 
presentation, those who
 
survived past the first 
120 days of therapy generally had good
 
outcomes thereafter, a phenomenon that has 
been observed among
 
adults in other 
developing-world settings [7]. 
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As has been described
 
in other regions [7], 
the result showed that surviving
 
patients 
generally have very good CD4-cell 
responses. The average
 
patient in the cohort 
experienced a more than doubling of his
 
or 
her CD4-cell count in the first 18 months of 
ART.  It was also observed that follow-up 
CD4-cells measurements were not done 
every 6 months for all patients eligible for 
repeat CD4-cell Count in accordance to the 
national ART guidelines [2]. On the average, 
these follow-up CD4-cells measurements 
were repeated in about two-third of the 
cases, hence the need for improvement in 
the adherence to the national treatment 
guideline [2]. 
 
Adherence to medication and lifestyle 
changes is a key factor to positive treatment 
outcome in the therapy of HIV/AIDS and this 
presents a challenge to both patients and 
healthcare providers [11-16]. The patients’ 
knowledge of the benefits of ART and 
consequences of non-adherence of a 
majority was found to be high and that might 
have enhanced medication adherence and 
possibly the survival of patients on ART. 
From the result in this treatment centre, it can 
be deduced that these patients were well 
educated and counselled on the basic facts 
about ART before or after treatment initiation. 
The respondents also reported a good 
therapeutic relationship with the healthcare 
providers which are considered very essential 
for a successful adherence to medications. 
Despite these and the fact that all the 
respondents were counseled on medication 
adherence before starting ART, adherence 
was still found to be poor, 73.8%, compared 
to the 100% recommended level of 
adherence required to achieve the goal of 
ART. This is consistent with a recent study of 
self-reported poor adherence (< 80%) [8]. 
With this level of adherence, good CD4 
responses were obtained which may be 
better with increasing level of adherence.  
 
The educational status of the participants 
was not found to be associated with 
adherence as their occupational status. This 
was consistent with the major reasons 
reported by the respondents for non-
adherence (busy working/at school). It was 
very remarkable to observe that pill burden, 
cost, out of stock of medicines at the 
dispensary and lack of understanding of how 
to take drugs, etc, were never given as 
reasons for non-adherence to medications by 
the respondents. Despite all these, 




The researchers were unable to create a 
control group and hence treatment outcome 
for every patient was assessed by comparing 
the pre-ART CD4-cells counts
 
and CD4-cells 
counts while on ART. Fluctuations in absolute 
CD4 count are known to occur and hence 
definite conclusions should be drawn from 
repeated measurements [17] but that was not 
the case with this study. The duration of 
treatment was calculated as the time 
difference between the date of first ART 
initiation and the last date of medication refill 
at the ART pharmacy. Patients’ last date of 
medication refill at the pharmacy was used as 
the date of death. The exact date of death 
could not be obtained since almost all death 
cases took place outside the hospital setting 
and was determined through contact tracing 
and home visits.  The actual causes of the 
death could also not be ascertained. There 
were cases of missing or incomplete records 
that hampered the study. Some aspects of 
data collection were based on self-report, 




In this setting, patients receiving ART showed 
significant improvements
 
in CD4-cell status 
and early CD4-cell response but adherence 
level was relatively poor. Patients were more 
stable on zidovudine-based or nevirapine-
based regimens compared to stavudine-
based or efavirenz-based regimens. Early 
mortality rate was high, indicating a need for 
early interventions. 
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